Key result
Transfemoral Medtronic CoreValve implantation into failing aortic bioprostheses reduced the mean gradient from 42 to 18 mm Hg with a 30-day mortality of 7.4%.
Why the study?
Does transcatheter aortic valve implantation using the Medtronic CoreValve system improve hemodynamics and provide a safe alternative in older high-risk patients with failing aortic valve bioprosthesis?
Observational (n=27)
Does transcatheter aortic valve implantation using the Medtronic CoreValve system improve hemodynamics and provide a safe alternative in older high-risk patients with failing aortic valve bioprosthesis?
Transfemoral valve-in-valve implantation using the Medtronic CoreValve is feasible, safe, and improves hemodynamics in high-risk older patients with failing bioprosthetic aortic valves.
Answers are grounded in this paper and cite their sources.
May support valve-in-valve TAVI in high-risk patients; leaves open randomized confirmation of safety and durability.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) using the Medtronic CoreValve (MCV) system might represent an alternative to conventional redo surgery in older high-risk patients with a failing aortic valve bioprosthesis. METHODS AND RESULTS: Symptomatic patients with failing aortic valve bioprosthesis, aged ≥65 years with a logistic EuroSCORE ≥10 % were considered for treatment. Local anesthesia was used to retrogradely implant the MCV system into the failing bioprosthetic valve. Clinical events were recorded and a transthoracic echocardiography was performed to evaluate the impact of MCV on hemodynamics after transcatheter aortic valve implantation. A total of 27 patients (aged 74.8±8 years, logistic EuroSCORE of 31±17%) were treated. In those with AS and AS and AR (n=25), the mean gradient declined from 42±16 mm Hg before to 18±8 mm Hg after MCV implantation (P<0.001), in those with AR the level declined by 2. There was no intraprocedural death and no procedural myocardial infarction. On the basis of the definitions of the Valvular Academic Research Consortium, the rate of major stroke was 7.4 %, of life-threatening bleeding 7.4%, of kidney failure stage III 7.4%, and of major access site complication 11.1 %, respectively. Within 30 days after the procedure, 2 patients died; 1 from stroke and 1 from cardiac failure (30-day mortality: 7.4%). CONCLUSIONS: These results suggest that transfemoral mcv implantation into a wide range of degenerated aortic bioprosthetic valves - irrespective of the failure mode - is feasible, safe, and improves hemodynamics in older patients with higher risk for conventional aortic valve redo surgery.
No takes yet. Share an insight, caveat, or question.
Linke et al. (2012) conducted an observational in Failing bioprosthetic aortic valves (n=27). Medtronic CoreValve (MCV) system was evaluated on mean gradient in patients with AS and AS and AR (p=<0.001). Transfemoral Medtronic CoreValve implantation into failing aortic bioprostheses reduced the mean gradient from 42 to 18 mm Hg with a 30-day mortality of 7.4%.
Synapse has enriched 10 related papers. Consider them for comparative context: